Patents by Inventor Patrick Daugherty

Patrick Daugherty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190119370
    Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.
    Type: Application
    Filed: August 23, 2018
    Publication date: April 25, 2019
    Inventors: Nancy Elizabeth Stagliano, James William West, Kathryn Kamath, Paul Henry Bessette, Fred Gluck, Jason Gary Sagert, Patrick Daugherty
  • Patent number: 10118961
    Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolyzed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolyzing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: November 6, 2018
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Nancy E. Stagliano, James William West, Kathryn Kamath, Paul Henry Bessette, Fred Gluck, Jason Gary Sagert, Patrick Daugherty
  • Patent number: 10059762
    Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolyzed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolyzing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: August 28, 2018
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Nancy Elizabeth Stagliano, James William West, Kathryn Kamath, Paul Henry Bessette, Fred Gluck, Jason Gary Sagert, Patrick Daugherty
  • Publication number: 20170081397
    Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.
    Type: Application
    Filed: August 24, 2016
    Publication date: March 23, 2017
    Inventors: Nancy E. Stagliano, James William West, Kathryn Kamath, Paul Bessette, Fred Gluck, Jason Gary Sagert, Patrick Daugherty
  • Patent number: 9453078
    Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolyzed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolyzing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: September 27, 2016
    Assignee: CYTOMX THERAPEUTICS, INC.
    Inventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Fred Gluck, Jason Sagert, Patrick Daugherty
  • Publication number: 20160228546
    Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.
    Type: Application
    Filed: April 28, 2016
    Publication date: August 11, 2016
    Inventors: Nancy Elizabeth Stagliano, James William West, Kathryn Kamath, Paul Henry Bessette, Fred Gluck, Jason Gary Sagert, Patrick Daugherty
  • Publication number: 20140024810
    Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.
    Type: Application
    Filed: September 26, 2013
    Publication date: January 23, 2014
    Inventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Fred Gluck, Jason Sagert, Patrick Daugherty
  • Publication number: 20130309230
    Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.
    Type: Application
    Filed: March 4, 2013
    Publication date: November 21, 2013
    Inventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Fred Gluck, Jason Sagert, Patrick Daugherty
  • Patent number: 8563269
    Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.
    Type: Grant
    Filed: December 9, 2011
    Date of Patent: October 22, 2013
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Frederick W. Gluck, Jason Sagert, Patrick Daugherty
  • Patent number: 8518404
    Abstract: Activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM) are provided. Activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM are provided. Furthermore, ABPs which contain a first TBM, a second TBM and a CM are provided. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. Further provided are libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. Further provided are ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: August 27, 2013
    Assignees: The Regents of the University of California, CytomX Therapeutics, Inc.
    Inventors: Patrick Daugherty, Nancy Stagliano, Jerry Thomas, Kathryn Kamath, James W. West, Sanjay Khare, Jason Sagert
  • Patent number: 8513390
    Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.
    Type: Grant
    Filed: April 25, 2012
    Date of Patent: August 20, 2013
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Fred Gluck, Jason Sagert, Patrick Daugherty
  • Publication number: 20120244154
    Abstract: Activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM) are provided. Activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM are provided. Furthermore, ABPs which contain a first TBM, a second TBM and a CM are provided. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. Further provided are libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. Further provided are ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use.
    Type: Application
    Filed: March 2, 2012
    Publication date: September 27, 2012
    Inventors: Patrick Daugherty, Nancy Stagliano, Jerry Thomas, Kathryn Kamath, James W. West, Sanjay Khare
  • Publication number: 20120237512
    Abstract: Activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM) are provided. Activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM are provided. Furthermore, ABPs which contain a first TBM, a second TBM and a CM are provided. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. Further provided are libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. Further provided are ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use.
    Type: Application
    Filed: March 6, 2012
    Publication date: September 20, 2012
    Inventors: PATRICK DAUGHERTY, NANCY STAGLIANO, JERRY THOMAS, KATHRYN KAMATH, JAMES W. WEST, SANJAY KHARE
  • Publication number: 20120237977
    Abstract: Activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM) are provided. Activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM are provided. Furthermore, ABPs which contain a first TBM, a second TBM and a CM are provided. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. Further provided are libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. Further provided are ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use.
    Type: Application
    Filed: March 2, 2012
    Publication date: September 20, 2012
    Inventors: Patrick Daugherty, Nancy Stagliano, Jerry Thomas, Kathryn Kamath, James W. West, Sanjay Khare
  • Publication number: 20120207756
    Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.
    Type: Application
    Filed: April 25, 2012
    Publication date: August 16, 2012
    Inventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Frederick W. Gluck, Jason Sagert, Patrick Daugherty
  • Publication number: 20120149061
    Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.
    Type: Application
    Filed: December 9, 2011
    Publication date: June 14, 2012
    Inventors: NANCY E. STAGLIANO, JAMES W. WEST, KATHRYN KAMATH, PAUL H. BESSETTE, FREDERICK W. GLUCK, JASON SAGERT, PATRICK DAUGHERTY
  • Publication number: 20100189651
    Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.
    Type: Application
    Filed: January 12, 2010
    Publication date: July 29, 2010
    Applicant: CytomX Therapeutics, LLC
    Inventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Frederick Gluck, Jason Sagert, Patrick Daugherty
  • Publication number: 20090304719
    Abstract: The present disclosure provides activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM). The present disclosure provides activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM. Furthermore the present disclosure also provides ABPs which contain a first TBM, a second TBM and a CM. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. The disclosure further provides libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. The disclosure further provides ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use.
    Type: Application
    Filed: August 21, 2008
    Publication date: December 10, 2009
    Inventors: Patrick Daugherty, Nancy Stagliano, Jerry Thomas, Kathryn Kamath, James W. West, Sanjay Khare
  • Publication number: 20070258954
    Abstract: The invention relates to methods of selecting proteins, out of large libraries, having desirable characteristics. Exemplified are methods of expressing enzymes and antibodies on the surface of host cells and selecting for desired activities. These methods have the advantage of speed and ease of operation when compared with current methods. They also provide, without additional cloning, a source of significant quantities of the protein of interest.
    Type: Application
    Filed: December 22, 2005
    Publication date: November 8, 2007
    Inventors: Brent Iverson, George Georgiou, Gang Chen, Mark Olsen, Patrick Daugherty
  • Publication number: 20070099247
    Abstract: Disclosed herein are expression vectors which display a passenger polypeptide on the outer surface of a biological entity. As disclosed herein the displayed passenger polypeptide is capable of interacting or binding with a given ligand. Also disclosed are methods of making and using the expression vectors. N/C terminal fusion expression vectors and methods of making and using are also disclosed.
    Type: Application
    Filed: December 19, 2006
    Publication date: May 3, 2007
    Inventors: Patrick Daugherty, Paul Bessette, Jeffrey Rice